Full metadata record
DC FieldValueLanguage
dc.creatorCaers, J. (Jo)-
dc.creatorPaiva, B. (Bruno)-
dc.creatorZamagni, E. (Elena)-
dc.creatorLeleu, X. (Xavier)-
dc.creatorBladé, J. (Joan)-
dc.creatorKristinsson, S.Y. (S. Y.)-
dc.creatorTouzeau, C. (C.)-
dc.creatorAbildgaard, N. (N.)-
dc.creatorTerpos, E. (Evangelos)-
dc.creatorHeusschen, R. (R.)-
dc.creatorOcio, E.M. (Enrique M.)-
dc.creatorDelforge, M. (M.)-
dc.creatorSezer, O. (O.)-
dc.creatorBeksac, M. (Meral)-
dc.creatorLudwig, H. (Heinz)-
dc.creatorMerlini, G. (G.)-
dc.creatorMoreau, P. (Philippe)-
dc.creatorZweegman, S. (Sonja)-
dc.creatorEngelhardt, M. (Monika)-
dc.creatorRosiñol, L. (Laura)-
dc.date.accessioned2023-03-09T08:37:57Z-
dc.date.available2023-03-09T08:37:57Z-
dc.date.issued2018-
dc.identifier.citationCaers, J. (Jo); Paiva, B. (Bruno); Zamagni, E. (Elena); et al. "Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel". Journal of hematology and oncology. 11 (10), 2018,es_ES
dc.identifier.issn1756-8722-
dc.identifier.urihttps://hdl.handle.net/10171/65654-
dc.description.abstractSolitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography–computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.es_ES
dc.description.sponsorshipThis work has been supported by grants from the Belgian Foundation against Cancer and the Fonds National de la Recherche Scientifique to Jo Caers. This work is further supported by the Deutsche Krebshilfe (grants 1095969 and 111424) (to Monika Engelhardt) and by Asociación Española Contra el Cáncer (GCB120981SAN) (to Bruno Paiva).es_ES
dc.language.isoenges_ES
dc.publisherBioMed Centrales_ES
dc.relationinfo:eu-repo/grantAgreement/NHMRC/Postgraduate Scholarships/1114242/AUes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectSolitary plasmacytomaes_ES
dc.subjectExtramedullary plasmacytomaes_ES
dc.subjectMyelomaes_ES
dc.subjectPlasma cell dyscrasiaes_ES
dc.subjectPET/CTes_ES
dc.subjectMRIes_ES
dc.subjectRadiotherapyes_ES
dc.titleDiagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Paneles_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.es_ES
dc.identifier.doi10.1186/s13045-017-0549-1-
dadun.citation.number10es_ES
dadun.citation.publicationNameJournal of hematology and oncologyes_ES
dadun.citation.volume11es_ES

Files in This Item:
Thumbnail
File
s13045-017-0549-1.pdf
Description
Size
473.14 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.